SCHEMBL10004150

SCHEMBL10004150

Cc1nc2c(c(OCC(F)(F)F)c(C(=O)O)n2C)c(=O)n1Cc1ccc(F)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 2/20 0.44
▸ POLB P06746 1/20 0.43
▸ TSHR P16473 6/20 0.38
▸ USP2 O75604 5/20 0.38
▸ CYP1A2 P05177 3/20 0.38
▸ CYP3A4 P08684 3/20 0.38
▸ CYP2C9 P11712 3/20 0.38
▸ ALDH1A1 P00352 3/20 0.38
▸ TP53 P04637 1/20 0.38
▸ MAPT P10636 2/20 0.38
▸ HTT P42858 2/20 0.38
▸ BLM P54132 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ CYP2C19 P33261 2/20 0.37
▸ HSD17B10 Q99714 2/20 0.37
▸ CASP1 P29466 1/20 0.37
▸ CASP7 P55210 1/20 0.37
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10004766 0.93 NPSR1 (0.42) NPSR1POLBTSHRUSP2ALDH1A1
SCHEMBL10004100 0.93 ALDH1A1 (0.44) NPSR1POLBTSHRUSP2CYP1A2
SCHEMBL10004914 0.92 MAPT (0.45) NPSR1TSHRUSP2CYP1A2ALDH1A1
SCHEMBL10004584 0.91 BLM (0.48) NPSR1POLBTSHRUSP2ALDH1A1
SCHEMBL10004501 0.90 ALDH1A1 (0.43) NPSR1POLBTSHRUSP2CYP1A2
SCHEMBL10003653 0.89 KMT2A (0.47) NPSR1ALDH1A1MAPTHSD17B10MEN1
SCHEMBL10004555 0.87 KMT2A (0.49) NPSR1TSHRALDH1A1TP53MAPT
SCHEMBL10004560 0.85 TDP1 (0.48) NPSR1POLBTSHRUSP2CYP1A2
SCHEMBL10004065 0.84 KMT2A (0.43) NPSR1POLBTSHRCYP1A2CYP3A4
SCHEMBL10004728 0.84 ALDH1A1 (0.45) TSHRUSP2CYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471793-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2016-10-05 — — EP disclosed
US-8614208-B2 Fused heterocyclic ring derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-12-24 — — US disclosed
US-20120214795-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-23 — — US disclosed
EP-2471793-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214795-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH NPSR1 2438/4885POLB 4723/4885TSHR 2374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback